OCTIMET Oncology

Name

OCTIMET Oncology

Legal name

OCTIMET Oncology NV

Website

https://octimet.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Targeted cancer therapy
• Kinase inhibitor drugs
• Oncology drug development
• Small molecule therapeutics
• MET pathway inhibitors

Headquarters

HQ city

Beerse

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

OCTIMET Oncology is a pre-clinical stage Belgian biopharmaceutical company developing highly selective small molecule MET kinase inhibitors (OMO-1 and OMO-2) licensed from Janssen Pharmaceutica for targeted cancer therapy. The company advances its candidates through regional licensing partnerships rather than direct commercialization, with Shanghai Allist Pharmaceuticals covering Greater China and DeuterOncology NV covering the Rest of the World.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Shanghai Allist Pharmaceuticals Co., Ltd.coreStrategic or Co-development PartnerOCTIMET has partnered OMO-1 and OMO-2 with Shanghai Allist Pharmaceuticals for Greater China region. Allist is a Shanghai-based pharmaceutical company focused on innovative drug development, particularly in oncology. This partnership grants Allist rights to develop, manufacture, and commercialize OCTIMET's MET kinase inhibitors in Greater China.
• DeuterOncology NVcoreStrategic or Co-development PartnerOCTIMET has partnered OMO-1 and OMO-2 with DeuterOncology NV for the Rest of the World (excluding Greater China). DeuterOncology is a Belgian biotech company. This partnership provides DeuterOncology rights to develop, manufacture, and commercialize OCTIMET's MET kinase inhibitors outside of Greater China.

Direct peers

• Blueprint Medicines: Clinical-stage biotech developing highly selective kinase inhibitors for cancer and rare diseases. Directly comparable as a small-molecule kinase-inhibitor oncology company pursuing differentiated selectivity profiles against validated and emerging oncogenic targets.
• Mirati Therapeutics: Targeted oncology company known for selective kinase inhibitors including MET/RAF programs. Highly comparable technology base and oncology focus; acquired by BMS, illustrating the acquisition exit pathway available to kinase-platform biotechs.
• Nuvalent: Clinical-stage biotech developing selective kinase inhibitors for oncology, with a notable focus on EGFR-driven lung cancer combinations. Comparable as a selectivity-focused kinase-inhibitor company with combination strategies relevant to OCTIMET's OMO-2 program.
• Erasca: Precision oncology company building a pipeline of small-molecule kinase inhibitors targeting the RAS/MAPK pathway and related nodes. Directly comparable scientifically to OCTIMET's RAS/MET targeting thesis and partnership-driven development model.
• Black Diamond Therapeutics: Clinical-stage targeted oncology company developing small-molecule kinase inhibitors against oncogenic driver mutations. Comparable as a target-discovery driven kinase-inhibitor oncology biotech with similar stage and GTM profile.
• Turning Point Therapeutics: Design-focused precision oncology company developing kinase inhibitors with optimized selectivity and CNS penetration. Acquired by BMS, providing another relevant M&A comparable for clinically successful kinase biotechs.
• Deciphera Pharmaceuticals: Built and commercialized multiple kinase-inhibitor oncology assets, ultimately acquired by Ono Pharmaceutical. Strongly comparable as a kinase-inhibitor specialist that progressed programs from preclinical through approval.

Emerging players

• C4 Therapeutics: Targeted oncology company developing small-molecule degraders and inhibitors against validated cancer targets. Comparable as a target-focused oncology platform pursuing differentiated selectivity/specificity profiles.

Broad incumbents

• Janssen Pharmaceutica (J&J): Original licensor of the MET inhibitor assets OMO-1 and OMO-2 and one of the largest oncology drug developers globally. Comparable as a benchmark for the originating big-pharma validation and as a potential future acquirer or partner.
• Merck KGaA: Markets the approved MET inhibitor tepotinib and develops oncology combination regimens involving MET pathway agents. Directly comparable as a developer and commercializer of selective MET inhibitors targeting lung cancer combinations.

Market position

Customer concentration

• LinkedInlinkedin.com/company/octimet-oncology-nv

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OCTIMET Oncology